| |
| |
|
| Insider
Information: |
Bolzon Bradley J Phd |
| Relationship: |
Director, 10% Owner |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
21,851 |
|
|
Indirect Shares
|
13,354,534 |
|
|
| Direct
Value |
$106,414 |
|
|
|
Indirect Value
|
$84,609,262 |
|
|
| Total
Shares |
13,376,385 |
|
|
| Total
Value |
$84,715,676 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -15.0%
|
-33.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Paratek Pharmaceuticals Inc |
PRTK |
10% Owner |
2006-05-15 |
0 |
2006-05-15 |
13,713 |
Premium* |
|
|
Flexion Therapeutics Inc |
FLXN |
Director, 10% Owner |
|
0 |
2014-02-18 |
3,206,807 |
Premium* |
|
|
Phaserx, Inc. |
PZRX |
10% Owner |
|
0 |
2016-05-23 |
1,931,094 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2021-06-29 |
0 |
2021-07-19 |
498,558 |
Premium* |
|
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director, 10% Owner |
2020-12-14 |
21,851 |
2020-12-14 |
5,606,424 |
Premium* |
|
|
Monte Rosa Therapeutics, Inc. |
GLUE |
Director, 10% Owner |
2021-06-28 |
0 |
2021-06-28 |
2,097,938 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
134 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PRTK |
Paratek Pharmaceuticals I... |
10% Owner |
– – • |
2006-05-15 |
4 |
B |
$0.00 |
$0 |
I/I |
230,769 |
2,044,744 |
1.42 |
- |
|
| PRTK |
Paratek Pharmaceuticals I... |
10% Owner |
– – • |
2006-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,843,899 |
13,713 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Director |
– • • |
2014-02-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,793,335 |
2,899,115 |
0 |
- |
|
| FLXN |
Flexion Therapeutics Inc |
Director |
– • • |
2014-02-18 |
4 |
B |
$13.00 |
$3,999,996 |
I/I |
307,692 |
3,206,807 |
2.25 |
- |
|
| PZRX |
Phaserx, Inc. |
10% Owner |
– – • |
2016-05-23 |
4 |
B |
$5.00 |
$3,000,000 |
I/I |
600,000 |
1,931,094 |
1.5 |
- |
|
| PZRX |
Phaserx, Inc. |
10% Owner |
– – • |
2016-05-23 |
4 |
S |
$0.01 |
$2,580 |
I/I |
(258,044) |
1,334,617 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
I/I |
6,508,699 |
79,478 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2016-10-24 |
4 |
B |
$14.00 |
$2,254,000 |
I/I |
161,000 |
185,987 |
2.1 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-09-05 |
4 |
A |
$0.00 |
$0 |
D/D |
55,447 |
55,447 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-09-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,614,157) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-09-05 |
4 |
A |
$0.00 |
$0 |
I/I |
311,052 |
1,240 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-11-24 |
4 |
AS |
$20.21 |
$30,450 |
D/D |
(1,507) |
53,940 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-11-27 |
4 |
AS |
$20.24 |
$4,048 |
D/D |
(200) |
53,740 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2017-12-22 |
4 |
AS |
$20.30 |
$528,237 |
D/D |
(26,016) |
27,724 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
92,918 |
92,918 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,262 |
43,986 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(592,918) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-23 |
4 |
AS |
$50.66 |
$5,168,901 |
I/I |
(101,994) |
117,173 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-24 |
4 |
AS |
$50.60 |
$1,164,655 |
I/I |
(22,841) |
115,645 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-26 |
4 |
AS |
$50.11 |
$10,553,782 |
I/I |
(210,610) |
101,559 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-27 |
4 |
AS |
$50.01 |
$582,655 |
I/I |
(11,648) |
100,780 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-04-30 |
4 |
AS |
$50.26 |
$1,537,138 |
I/I |
(30,566) |
98,736 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-07 |
4 |
AS |
$50.31 |
$6,030,826 |
I/I |
(119,709) |
90,730 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-08 |
4 |
AS |
$50.16 |
$467,067 |
D/D |
(9,241) |
34,745 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2018-05-15 |
4 |
S |
$57.97 |
$2,551,440 |
I/I |
(44,000) |
640,014 |
0 |
- |
|
134 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
